00014 A PHASE II STUDY OF THE AGO OVARIAN CANCER STUDY GROUP (AGO-OVAR 2.6): ZD1839 IN COMBINATION WITH TAMOXIFEN IN REFRACTORY OVARIAN CANCER. (1st September 2005) - Sehouli, J.; Wagner, U.; du Bois, A.; Pfisterer, J.; Houber, J.; Loibl, S.; Lueck, H. J.; Gropp, M.; Staehle, A.; Schmalfeldt, B.; Meier, W.; Jackisch, C.